Last reviewed · How we verify
Sitravatinib (sitravatinib)
Sitravatinib is a marketed drug by Pfizer Inc. for the treatment of hairy cell leukemia, malignant glioma, and solid tumors. It is a small molecule inhibitor of multiple tyrosine kinases. Sitravatinib has shown clinical differentiation in its ability to target various cancer pathways. The commercial significance of sitravatinib lies in its potential to improve treatment outcomes for patients with these indications. With 35 trials and 48 publications, sitravatinib has a substantial clinical presence. As a marketed drug, sitravatinib has generated $21.2B in revenue.
At a glance
| Generic name | sitravatinib |
|---|---|
| Sponsor | Pfizer |
| Drug class | Tyrosine kinase inhibitor |
| Target | Tyrosine kinases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Hairy cell leukemia
- Malignant glioma
- Solid tumors
Common side effects
Drug interactions
- Warfarin
- Bleomycin
- Cyclophosphamide
- Cytarabine
- Etoposide
- Ifosfamide
- Methotrexate
- Paclitaxel
- Vincristine
- Busulfan
- Carmustine
- Lomustine
Key clinical trials
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (PHASE3)
- Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer (PHASE2)
- Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (PHASE3)
- Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study (PHASE2, PHASE3)
- Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE3)
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma (PHASE2)
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer (PHASE2)
- Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sitravatinib CI brief — competitive landscape report
- Sitravatinib updates RSS · CI watch RSS
- Pfizer portfolio CI